Latest Findings on Prediction and Prevention of Preeclampsia

YE Yun-zhen, ZHOU Qiong-jie, XIAO Xi-rong, XIONG Yu, LI Xiao-tian

Abstract

Preeclampsia, a progressive disease involving multiple systems, afflicts pregnancy specifically. It contributes to severe maternal and perinatal morbidity and mortality. It has been reported that preeclampsia initiates from a mismatch between the utero-placental supply and demand, which subsequently triggers the release of placental syncytiotrophoblast stress-derived factors and an imbalance of proangiogenic/antiangiogenic factors, eventually causing maternal systemic endothelial lesions and systemic inflammatory response. Currently, treatments available for preeclampsia are very limited in number. Hence, prediction and prevention carry special significance. Herein, we reviewed the current understanding of preeclampsia, especially findings on the prediction and prevention of preeclampsia published within the past 5 years. We discussed the Fetal Medicine Foundation (FMF) screening model based on placental growth factor (PlGF) and the effects of aspirin, calcium, exercise, and termination of pregnancy in preventing preeclampsia. The efficacy and safety of other new preventive measures still need further validation.

 

Keywords: Preeclampsia, Prediction, Prevention

 

Full Text:

PDF


References


GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet，2016， 388(10053): 1603–1658.

REALE S C， CAMANN W R. Preeclampsia. NEJM，2022，387(3): 286–287.

DULEY L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol，2009，33(3): 130–137.

ROLNIK D L， WRIGHT D， POON L C， et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. NEJM，2017，377(7): 613–622.

WRIGHT D， WRIGHT A， NICOLAIDES K H. The competing risk approach for prediction of preeclampsia. Am J Obstet Gynecol，2020， 223(1): 12–23.e17.

AL-RUBAIE Z， ASKIE L M， RAY J G， et al. The performance of risk prediction models for pre-eclampsia using routinely collected maternal characteristics and comparison with models that include specialised tests and with clinical guideline decision rules: A systematic review. BJOG， 2016，123(9): 1441–1452.

DÖBERT M， WRIGHT A， VAROUXAKI A N， et al. STATIN trial: Predictive performance of competing-risks model in screening for pre-eclampsia at 35-37 weeks' gestation. Ultrasound Obstet Gynecol，2022， 59(1): 69–75.

ZEISLER H， LLURBA E， CHANTRAINE F， et al. Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia. NEJM，2016， 374(1): 13–22.

DULEY L， MEHER S， HUNTER K E， et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev，2019，2019(10): CD004659.

HASTIE R， TONG S， WIKSTRÖM A K， et al. Aspirin use during pregnancy and the risk of bleeding complications: A Swedish population-based cohort study. Am J Obstet Gynecol，2021，224(1): 95.e91–95.e12.

KINSHELLA M W， SARR C， SANDHU A， et al. Calcium for pre-eclampsia prevention: A systematic review and network meta-analysis to guide personalised antenatal care. BJOG，2022，129(11): 1833–1843.

GROBMAN W A， RICE M M， REDDY U M， et al. Labor induction versus expectant management in low-risk nulliparous women. NEJM， 2018，379(6): 513–523.

HERSH A R， SKEITH A E， SARGENT J A， et al. Induction of labor at 39 weeks of gestation versus expectant management for low-risk nulliparous women: A cost-effectiveness analysis. Am J Obstet Gynecol， 2019，220(6): 590.e591–590.e510.

CUDMORE M， AHMAD S， AL-ANI B， et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation，2007，115(13): 1789–1797.

BERGMANN A， AHMAD S， CUDMORE M， et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med，2010，14(6b): 1857–1867.

DÖBERT M， VAROUXAKI A N， MU A C， et al. Pravastatin versus placebo in pregnancies at high risk of term preeclampsia. Circulation， 2021，144(9): 670–679.

WEN S W， WHITE R R， RYBAK N， et al. Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind， phase Ⅲ， randomised controlled， international， multicentre trial. BMJ， 2018， 362: k3478[2022-03-21]. https://doi.org/10.1136/bmj.k3478.

CRUZ-LEMINI M， VÁZQUEZ J C， ULLMO J， et al. Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: A systematic review and meta-analysis. Am J Obstet Gynecol，2022，226(2S): S1126–S1144.e17.

TONG S， KAITU'U-LINO T J， HASTIE R， et al. Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: New horizons for the prevention or treatment of preeclampsia. Am J Obstet Gynecol， 2022，226(2S): S1157–S1170.


Refbacks

  • There are currently no refbacks.